Comparison · NCT00613626-sae
Arm B: ZD6474 vs Arm A: ZD6474 Matched Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm B: ZD6474 vs Arm A: ZD6474 Matched Placebo: serious adverse events. Trial comparisons, record NCT00613626-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00613626-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.341 | 0.216 | 0.495 | wilson | |
| Risk in group 2 | 0.242 | 0.128 | 0.41 | wilson | |
| Risk difference, group 1 minus group 2 | 0.099 | -0.111 | 0.29 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.41 | 0.673 | 2.95 | log | |
| Odds ratio, group 1 over group 2 | 1.62 | 0.581 | 4.52 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Arm B: ZD6474 than on Arm A: ZD6474 Matched Placebo | 10.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm B: ZD6474 | Subjects will receive cisplatin 60 mg/m2 IV day 1 plus etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles plus ZD6474 100mg oral daily to be continued for the duration of the study. Prophylactic antiemetics will be given at the discretion of the treating investigator.~Cisplatin: Cisplatin 60 mg/m2 IV day 1 every 21 days for a total of 4 cycles~Etoposide: Etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles~ZD6474: ZD6474 100mg oral daily to be continued for the duration of the study. | 14 | 41 | EG001 |
| Group 2 | Arm A: ZD6474 Matched Placebo | Subjects will receive cisplatin 60 mg/m2 IV day 1 plus etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles plus ZD6474 matched placebo oral daily to be continued for the duration of the study. Prophylactic antiemetics will be given at the discretion of the treating investigator.~Cisplatin: Cisplatin 60 mg/m2 IV day 1 every 21 days for a total of 4 cycles~Etoposide: Etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles~Placebo: Matched placebo oral daily | 8 | 33 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
- NCT number
- NCT00613626
- Phases
- PHASE2
- Conditions
- Small Cell Lung Cancer
- Interventions
- Cisplatin, Etoposide, Placebo, ZD6474
- Lead sponsor
- Hoosier Cancer Research Network
- Results first posted
- 2015-11-18
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00613626?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00613626-sae